These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31619281)

  • 21. Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
    Lotan Y; de Jong JJ; Liu VYT; Bismar TA; Boorjian SA; Huang HC; Davicioni E; Mian OY; Wright JL; Necchi A; Dall'Era MA; Kaimakliotis HZ; Black PC; Gibb EA; Boormans JL
    J Urol; 2022 Mar; 207(3):541-550. PubMed ID: 34643090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.
    de Jong JJ; Liu Y; Boorjian SA; Bivalacqua TJ; Porten SP; Wheeler T; Davicioni E; Svatek RS; Boormans JL; Black PC; Lotan Y; Gibb EA
    J Urol; 2020 Aug; 204(2):239-246. PubMed ID: 32074006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long noncoding RNAs to predict postoperative recurrence in bladder cancer and to develop a new molecular classification system.
    Li Z; Jiang L; Zhang Z; Deng M; Wei W; Tang H; Guo S; Ye Y; Yao K; Liu Z; Zhou F
    Cancer Med; 2022 Jan; 11(2):539-552. PubMed ID: 34816620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
    Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
    Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
    Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
    Seiler R; Gibb EA; Wang NQ; Oo HZ; Lam HM; van Kessel KE; Voskuilen CS; Winters B; Erho N; Takhar MM; Douglas J; Vakar-Lopez F; Crabb SJ; van Rhijn BWG; Fransen van de Putte EE; Zwarthoff EC; Thalmann GN; Davicioni E; Boormans JL; Dall'Era M; van der Heijden MS; Wright JL; Black PC
    Clin Cancer Res; 2019 Aug; 25(16):5082-5093. PubMed ID: 30224344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.
    Worst TS; Weis CA; Stöhr R; Bertz S; Eckstein M; Otto W; Breyer J; Hartmann A; Bolenz C; Wirtz RM; Erben P
    Sci Rep; 2018 Sep; 8(1):14383. PubMed ID: 30258198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Characterization of Neuroendocrine-like Bladder Cancer.
    Batista da Costa J; Gibb EA; Bivalacqua TJ; Liu Y; Oo HZ; Miyamoto DT; Alshalalfa M; Davicioni E; Wright J; Dall'Era MA; Douglas J; Boormans JL; Van der Heijden MS; Wu CL; van Rhijn BWG; Gupta S; Grivas P; Mouw KW; Murugan P; Fazli L; Ra S; Konety BR; Seiler R; Daneshmand S; Mian OY; Efstathiou JA; Lotan Y; Black PC
    Clin Cancer Res; 2019 Jul; 25(13):3908-3920. PubMed ID: 30952638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delays in radical cystectomy for muscle-invasive bladder cancer.
    Chu AT; Holt SK; Wright JL; Ramos JD; Grivas P; Yu EY; Gore JL
    Cancer; 2019 Jun; 125(12):2011-2017. PubMed ID: 30840335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.
    van der Vos KE; Vis DJ; Nevedomskaya E; Kim Y; Choi W; McConkey D; Wessels LFA; van Rhijn BWG; Zwart W; van der Heijden MS
    Sci Rep; 2020 Jul; 10(1):10952. PubMed ID: 32616859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
    Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y
    Med Oncol; 2014 May; 31(5):949. PubMed ID: 24700028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Pichler R; Lindner AK; Compérat E; Obrist P; Schäfer G; Todenhöfer T; Horninger W; Culig Z; Untergasser G
    Am J Pathol; 2020 Feb; 190(2):442-452. PubMed ID: 31843500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of long non-coding RNAs that stimulate cell survival in bladder cancer.
    Dudek AM; Boer SJ; Boon N; Witjes JA; Kiemeney LALM; Verhaegh GW
    Oncotarget; 2017 May; 8(21):34442-34452. PubMed ID: 28415801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer.
    Nitschke K; Worst TS; von Rhade SM; Thaqi B; Neuberger M; Wessels F; Weis CA; Porubsky S; Gaiser T; Kriegmair M; von Hardenberg J; Weidenbusch M; Erben P; Nuhn P
    Urol Oncol; 2021 Aug; 39(8):499.e1-499.e8. PubMed ID: 34134925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
    Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
    Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Slow N-acetylation as a possible contributor to bladder carcinogenesis.
    El Kawak M; Dhaini HR; Jabbour ME; Moussa MA; El Asmar K; Aoun M
    Mol Carcinog; 2020 Sep; 59(9):1017-1027. PubMed ID: 32529781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lövgren K; Marzouka NA; Olsson H; Höglund M; Ullén A; Liedberg F
    Eur Urol; 2022 May; 81(5):523-532. PubMed ID: 34782206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group.
    Gild P; Vetterlein MW; Seiler R; Necchi A; Hendricksen K; Mertens LS; Roghmann F; Landenberg NV; Gontero P; Cumberbatch M; Dobruch J; Seisen T; Grande P; D'Andrea D; Anract J; Comploj E; Pycha A; Saba K; Poyet C; van Rhijn BW; Noon AP; Roupret M; Shariat SF; Fisch M; Xylinas E; Rink M
    Surg Oncol; 2020 Sep; 34():312-317. PubMed ID: 32891350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
    Choi W; Porten S; Kim S; Willis D; Plimack ER; Hoffman-Censits J; Roth B; Cheng T; Tran M; Lee IL; Melquist J; Bondaruk J; Majewski T; Zhang S; Pretzsch S; Baggerly K; Siefker-Radtke A; Czerniak B; Dinney CP; McConkey DJ
    Cancer Cell; 2014 Feb; 25(2):152-65. PubMed ID: 24525232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.